Development of myasthenia gravis in a patient with multiple sclerosis during treatment with glatiramer acetate

J Neurol. 2000 Sep;247(9):713. doi: 10.1007/s004150070118.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Autoantibodies
  • Female
  • Glatiramer Acetate
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Immunosuppressive Agents / therapeutic use
  • Multiple Sclerosis / drug therapy*
  • Myasthenia Gravis / chemically induced*
  • Peptides / adverse effects*
  • Peptides / therapeutic use

Substances

  • Autoantibodies
  • Immunosuppressive Agents
  • Peptides
  • Glatiramer Acetate